See more : Bureau Veritas SA (BVI.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Blau Farmacêutica S.A. (BLAU3.SA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Blau Farmacêutica S.A., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Bank of the Philippine Islands (BPHLY) Income Statement Analysis – Financial Results
- Shenzhen JPT Opto-Electronics Co., Ltd. (688025.SS) Income Statement Analysis – Financial Results
- SK Growth Opportunities Corporation (SKGRW) Income Statement Analysis – Financial Results
- SU Group Holdings Limited Ordinary Shares (SUGP) Income Statement Analysis – Financial Results
- OPKO Health, Inc. (OPK) Income Statement Analysis – Financial Results
Blau Farmacêutica S.A. (BLAU3.SA)
About Blau Farmacêutica S.A.
Blau Farmacêutica S.A., a pharmaceutical company provides private label drugs in Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. The company's medications cover various therapeutic classes, such as immunology, hematology, oncology, nephrology, specialties, and antibiotics. It also offers biological drugs; oral and injectable drugs for treating cancer; specialized treatments for infectious diseases; and prescription and non-prescription drugs, including dermo-medicines, condoms, and others for retail and non-retail markets. In addition, the company provides blood-derived, biological, biotechnological, and antiretroviral drugs. It serves hospitals, private clinics, chemotherapy and hemodialysis centers, and public health institutions. The company was incorporated in 1987 and is headquartered in Cotia, Brazil.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.37B | 1.41B | 1.37B | 1.18B | 977.50M | 782.16M | 617.66M | 430.93M | 383.45M |
| Cost of Revenue | 908.33M | 739.03M | 700.47M | 625.84M | 547.44M | 443.91M | 337.22M | 251.57M | 223.20M |
| Gross Profit | 464.30M | 667.88M | 665.93M | 555.97M | 430.07M | 338.26M | 280.43M | 179.37M | 160.25M |
| Gross Profit Ratio | 33.83% | 47.47% | 48.74% | 47.04% | 44.00% | 43.25% | 45.40% | 41.62% | 41.79% |
| Research & Development | 42.40M | 38.91M | 52.12M | 28.54M | 11.96M | 15.28M | 12.25M | 13.59M | 0.00 |
| General & Administrative | 140.37M | 109.72M | 98.34M | 78.85M | 62.51M | 86.37M | 79.02M | 89.17M | 0.00 |
| Selling & Marketing | 86.52M | 104.13M | 103.43M | 53.97M | 52.72M | 40.77M | 35.31M | 22.28M | 0.00 |
| SG&A | 226.88M | 213.85M | 201.77M | 132.82M | 115.23M | 127.14M | 114.33M | 111.45M | 104.20M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.74M | -2.55M | -1.55M | -1.12M |
| Operating Expenses | 252.76M | 215.68M | 207.18M | 166.29M | 128.78M | 135.24M | 116.10M | 111.19M | 105.31M |
| Cost & Expenses | 1.16B | 954.71M | 907.66M | 792.13M | 676.21M | 579.15M | 453.33M | 362.76M | 328.51M |
| Interest Income | 55.80M | 70.22M | 34.95M | 5.23M | 6.24M | 2.53M | 563.00K | 321.00K | 326.00K |
| Interest Expense | 37.58M | 32.43M | 26.80M | 15.32M | 15.12M | 17.26M | 11.78M | 19.39M | 21.58M |
| Depreciation & Amortization | 38.89M | 22.29M | 20.69M | 17.17M | 9.93M | 10.24M | 8.92M | 8.73M | 7.68M |
| EBITDA | 410.55M | 527.04M | 533.30M | 388.71M | 312.50M | 206.76M | 170.42M | 76.14M | 53.38M |
| EBITDA Ratio | 29.91% | 38.02% | 37.41% | 32.50% | 31.84% | 26.22% | 27.48% | 19.85% | 16.33% |
| Operating Income | 211.54M | 512.60M | 490.24M | 366.91M | 301.29M | 194.84M | 160.84M | 76.79M | 54.94M |
| Operating Income Ratio | 15.41% | 36.43% | 35.88% | 31.05% | 30.82% | 24.91% | 26.04% | 17.82% | 14.33% |
| Total Other Income/Expenses | 122.70M | 53.45M | 72.55M | -11.89M | -14.79M | -16.44M | -14.60M | -20.19M | -30.40M |
| Income Before Tax | 334.23M | 468.56M | 482.47M | 353.64M | 286.36M | 178.40M | 148.49M | 45.94M | 24.12M |
| Income Before Tax Ratio | 24.35% | 33.30% | 35.31% | 29.92% | 29.30% | 22.81% | 24.04% | 10.66% | 6.29% |
| Income Tax Expense | 86.74M | 108.07M | 158.60M | 99.31M | 86.13M | 55.15M | 45.36M | 13.61M | 1.34M |
| Net Income | 249.81M | 363.37M | 325.22M | 254.33M | 200.24M | 123.25M | 103.13M | 32.33M | 23.06M |
| Net Income Ratio | 18.20% | 25.83% | 23.80% | 21.52% | 20.48% | 15.76% | 16.70% | 7.50% | 6.01% |
| EPS | 1.41 | 2.02 | 1.81 | 1.45 | 1.35 | 0.70 | 0.59 | 0.18 | 0.12 |
| EPS Diluted | 1.41 | 2.02 | 1.81 | 1.45 | 1.35 | 0.70 | 0.59 | 0.18 | 0.12 |
| Weighted Avg Shares Out | 177.68M | 179.39M | 179.39M | 175.30M | 148.00M | 175.30M | 175.30M | 175.30M | 198.00M |
| Weighted Avg Shares Out (Dil) | 177.68M | 179.39M | 179.39M | 175.30M | 148.13M | 175.30M | 175.30M | 175.30M | 198.00M |
Source: https://incomestatements.info
Category: Stock Reports